Nucleic acid

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on: 
Tuesday, February 20, 2024
Organic chemistry, Therapy, Bachelor of Science, Cancer, Alnylam Pharmaceuticals, Lakehead University, Senior, Enzyme, Doctor of Philosophy, Gene editing, Biotechnology, SAB, McGill University, Biocatalysis, Research and development, ANA, ECO, Masad, International Society, Oligonucleotide, Codexis, RNA, Nucleic acid, Central Waqf Council, Patient, Texas A&M University, About us, Infection, Editorial board, Publication, Development, Laboratory, Masad Damha, Management

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points: 
  • This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
  • “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
  • Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
  • Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

Global Molecular Diagnostics Market for Infectious Disease Analysis and Executive Guides 2023-2027: Assessing the Growing Demand for Rapid Diagnostic Solutions in Various Healthcare Settings - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, Health, Health Technology, Other Science, Medical Devices, Research, Infectious Diseases, Hospitals, Genetics, Science, COVID-19, Analysis, Infection, Drug resistance, Nucleic acid, Blood, MDX, Country, Syndrome, Genomics, Diagnosis, Vertically transmitted infection, Molecular diagnostics, Pharmaceutical industry

The global market for molecular diagnostics (MDx) in infectious diseases is analyzed across various dimensions in this report.

Key Points: 
  • The global market for molecular diagnostics (MDx) in infectious diseases is analyzed across various dimensions in this report.
  • It begins with an overview of the global market by country, providing insights into regional trends and dynamics.
  • The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth.
  • A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe.

Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

Retrieved on: 
Tuesday, January 16, 2024
Fortification, Research, PSMA, Mol, Intrinsic termination, MicroRNA, Gene, NKG2D, Public expenditure, CD19, Nucleic acid, Investment, Intellectual property, BCMA, Vaccine

MONT-SAINT-GUIBERT, Belgium, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.

Key Points: 
  • Three main pillars to unlock the potential of proprietary technology platforms and intellectual property:
    MONT-SAINT-GUIBERT, Belgium, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
  • Michel Lussier, interim Chief Executive Officer of Celyad Oncology, commented: “2023 has been a very important year for Celyad Oncology, after the changes that occurred in 2022.
  • We have shared new data at several scientific and business conferences along the year, and published in high impact peer-reviewed journals.
  • Celyad Oncology will attend the 7th CAR-TCR Europe summit in London, UK (February 27-29, 2024), the must-attend forum to brainstorm and stay at the forefront of cell therapy innovations.

Eleven Therapeutics Welcomes Dr. Paloma H Giangrande as Chief Technology Officer

Retrieved on: 
Thursday, January 11, 2024
Entrepreneurship, DSM-IV codes, Specialization, Therapy, Research, Biotechnology, RNA, University, Nucleic acid, TEL, Molecule, Messenger, Medical device

CAMBRIDGE, Mass, CAMBRIDGE, England and TEL AVIV, Israel, Jan. 11, 2024 /PRNewswire/ -- Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr. Paloma H Giangrande as the company's Chief Technology Officer (CTO).

Key Points: 
  • CAMBRIDGE, Mass, CAMBRIDGE, England and TEL AVIV, Israel, Jan. 11, 2024 /PRNewswire/ -- Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr. Paloma H Giangrande as the company's Chief Technology Officer (CTO).
  • Bringing a wealth of experience, Dr. Giangrande has been a prominent figure in nucleic acid therapeutics for over a decade.
  • Prof. Yaniv Erlich, CEO and Co-Founder of Eleven Therapeutics, expressed his enthusiasm about Dr. Giangrande joining the team, stating, "We are thrilled to welcome Dr. Paloma Giangrande to Eleven Therapeutics.
  • Dr. Giangrande will officially assume her role as Chief Technology Officer at Eleven Therapeutics on January 2nd, 2024.

Celyad Oncology reports third quarter 2023 financial results and recent business highlights

Retrieved on: 
Thursday, November 9, 2023
CD95, CAR, NKG2D, 2023 International Conference on Climate Resilient Pakistan, RNA, Graft-versus-host disease, Public expenditure, CD19, ICLE, Conference, PD-1, Autophagy, Research, Mont-Saint-Guibert, Nucleic acid, SITC, Immunotherapy, Intrinsic termination, MicroRNA, Fortification, Dumont, B-ALL, Gene, Society, Anti-CD19 immunotoxin, PSMA, Patient, BCMA, Lymphocyte, Vaccine, Bank, Medical device, Euronext

“Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.

Key Points: 
  • “Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.
  • Celyad Oncology has relocated from September 25, 2023 into a new research facility which fits better its current needs after the strategic shift.
  • The Company remains headquartered at the Axis Parc, Mont-Saint-Guibert, Belgium but with its new business location at Dumont 9.
  • Net cash burn during the third quarter of 2023 amounted to €2.7 million, in line with expectations.

Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

Retrieved on: 
Monday, September 18, 2023
Human, AL, Osteopetrosis, University, RNA, Bone disease, Autosome, Nucleic acid, Messenger, Small RNA, University of L'Aquila, Bone, House, American Society for Bone and Mineral Research, Patient, Annual general meeting, Mouse, Silicon, LNP (newspaper), FDA, Phenotype, IND, Society, Safety, Pharmaceutical industry, Medical imaging, Vaccine

These results could have significant translational impact on bone disease therapies and open the path to human trials of SiSaf’s potentially curative treatment for Osteopetrosis ADO2.

Key Points: 
  • These results could have significant translational impact on bone disease therapies and open the path to human trials of SiSaf’s potentially curative treatment for Osteopetrosis ADO2.
  • There are currently no approved treatments for this debilitating disease and no other treatments currently in clinical trials.
  • SIS-101-ADO, SiSaf’s lead in house program, is an ADO2-specific siRNA specifically designed against the human CLCN7G215R mRNA formulated with the company’s sshLNP.
  • In addition, due to the serious manifestations of this rare skeletal disorder in children, the FDA granted SIS-101-ADO Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis.

Jennifer Meade Named President at Aldevron

Retrieved on: 
Monday, September 11, 2023
Biotechnology, Nucleic acid, Boston University School of Public Health, Patient, Meade, Breast, Health, Union College, Questrom School of Business, NYSE, HOLX, Nursing, Science, Biology

FARGO, N.D., Sept. 11, 2023 /PRNewswire/ -- Jennifer Meade has been named President of Aldevron, effective September 11th 2023, as part of a planned leadership transition.

Key Points: 
  • FARGO, N.D., Sept. 11, 2023 /PRNewswire/ -- Jennifer Meade has been named President of Aldevron, effective September 11th 2023, as part of a planned leadership transition.
  • "It is an honor and privilege to lead the Aldevron team at this pivotal time," Jennifer Meade, President of Aldevron.
  • Since joining Aldevron in October 2022 as General Manager, Nucleic Acids, Meade has been an active leader of Aldevron strategic initiatives including expanding the company's commercial footprint, championing process improvements to better serve the market,
    "It is an honor and privilege to lead the Aldevron team at this pivotal time," Meade said.
  • "Aldevron is a key partner to clients working to bring life-changing therapies to countless patients whose lives depend on biotechnology breakthroughs.

Rznomics Presents Its Own Circular RNA Platform Technology

Retrieved on: 
Thursday, August 3, 2023
Sequence, Vaccine, GOI, Therapy, Gene, Small RNA, Nucleotide, COVID-19, National Research Foundation of Korea, Circular permutation in proteins, RNA, STS, Ministry of Science, ICT and Future Planning, PIE, Research, Nucleic acid, National Research Foundation, Messenger, Ministry, ICT, Patent, IGS, Cell, DOI, Circular RNA, Exon, Society, American Society of Gene and Cell Therapy, Platform

SEONGNAM, South Korea, Aug. 3, 2023 /PRNewswire/ -- Rznomics developed a novel platform technology termed 'self-circularized RNA structure' that can efficiently and simply generate circular RNA and overcome the limitations of existing technology.

Key Points: 
  • SEONGNAM, South Korea, Aug. 3, 2023 /PRNewswire/ -- Rznomics developed a novel platform technology termed 'self-circularized RNA structure' that can efficiently and simply generate circular RNA and overcome the limitations of existing technology.
  • To overcome the drawbacks of the conventional linear RNAs mentioned above, circular RNA structure technology has recently attracted attention.
  • Rznomics has developed a new circular RNA manufacturing technology that uses group I intron ribozyme as well.
  • Rznomics applied its unique Tetrahymena trans-splicing ribozyme platform technology to effectively convert linear RNA into circular RNA by designing end-to-end self-targeting and splicing (STS) reaction.

Rznomics Presents Its Own Circular RNA Platform Technology

Retrieved on: 
Thursday, August 3, 2023
Sequence, Vaccine, GOI, Therapy, Gene, Small RNA, Nucleotide, COVID-19, National Research Foundation of Korea, Circular permutation in proteins, RNA, STS, Ministry of Science, ICT and Future Planning, PIE, Research, Nucleic acid, National Research Foundation, Messenger, Ministry, ICT, Patent, IGS, Cell, DOI, Circular RNA, Exon, Society, American Society of Gene and Cell Therapy, Platform

SEONGNAM, South Korea, Aug. 3, 2023 /PRNewswire/ -- Rznomics developed a novel platform technology termed 'self-circularized RNA structure' that can efficiently and simply generate circular RNA and overcome the limitations of existing technology.

Key Points: 
  • SEONGNAM, South Korea, Aug. 3, 2023 /PRNewswire/ -- Rznomics developed a novel platform technology termed 'self-circularized RNA structure' that can efficiently and simply generate circular RNA and overcome the limitations of existing technology.
  • To overcome the drawbacks of the conventional linear RNAs mentioned above, circular RNA structure technology has recently attracted attention.
  • Rznomics has developed a new circular RNA manufacturing technology that uses group I intron ribozyme as well.
  • Rznomics applied its unique Tetrahymena trans-splicing ribozyme platform technology to effectively convert linear RNA into circular RNA by designing end-to-end self-targeting and splicing (STS) reaction.

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing

Retrieved on: 
Thursday, June 29, 2023
MSD, DNA, MC3, APS, Serum, Gene editing, Mutation, IL-6, IL10, PNA, Dietrich Stephan, Development, IL-8, Blood, Immune system, Nucleic acid, Frameshift mutation, NHP, Cytokine, Research, LNP, Therapy, Death, Oligonucleotide, Pharmacology, Genome, Vaccine, Palladium, Stealth

For these reasons, we are on a mission to develop the next generation of editors that are non-immunogenic,” continued Dr. Stephan.

Key Points: 
  • For these reasons, we are on a mission to develop the next generation of editors that are non-immunogenic,” continued Dr. Stephan.
  • The conclusion from these data is that Stealth Editors do not elicit innate nor acquired immune responses in the encapsulated format in which they would be administered systemically.
  • The Company believes this is likely to be an important differentiator of its technology when transitioned to in vivo gene editing.
  • Ex vivo Editing with Stealth Editors - The Company investigated the capabilities of a new editing system to effectively edit human cells ex vivo.